Insulin hybrid peptide containing chymotrypsin inhibitory peptide and application thereof
Patent Information
- Application Number
- CN202380028608.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-29
- Filing Date
- 2023-05-29
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technology is difficult to overcome the short half-life of insulin in the body and difficulty in oral administration, resulting in diabetic patients requiring frequent insulin injections and low bioavailability of oral insulin.
A hybrid peptide containing chymotrypsin inhibitory peptide and insulin or its analogues was designed, which was connected through a connecting peptide to enhance the stability of insulin and promote its absorption in the small intestine and its entry into the blood circulation.
It improves the stability of insulin and the bioavailability of oral administration, reduces side effects, enhances patient compliance, and has economic advantages.
Smart Images

Figure CN118946593A_ABST
Abstract
Description
An insulin hybrid peptide containing a chymotrypsin inhibitory peptide and its application Technical Field This invention belongs to the field of protein engineering and relates to polypeptide molecules that inhibit chymotrypsin. It further relates to hybrid peptides formed by chymotrypsin inhibitory peptides and insulin molecules or their analogs, as well as their polyethylene glycol-modified, acylated, or amidated analogs or pharmaceutically acceptable salts thereof. The insulin hybrid peptide retains its chymotrypsin-inhibiting activity, thereby improving its stability and efficacy when administered in vivo. It can resist degradation by small intestinal metabolic enzymes, promoting direct absorption into the bloodstream via the small intestine, thus enabling oral administration of the hybrid peptide of insulin or its analogs. Background Technology Insulin is a hormone secreted by the pancreas that controls blood sugar levels. It transports excess glucose from the blood to cells to provide energy and maintain normal blood sugar levels. However, due to insulin deficiency, insulin resistance, and loss of beta cell function, people with diabetes cannot maintain normal insulin function. Therefore, they cannot use blood glucose as an energy source and instead exhibit hyperglycemia (high glucose levels) and excrete glucose in their urine, leading to various complications. Thus, people with diabetes who have abnormal insulin secretion (type 1 diabetes) or insulin resistance (type 2 diabetes) essentially require insulin therapy; by injecting insulin, they can maintain normal blood sugar levels. Because insulin has an extremely short half-life in the body, like other proteins and peptide hormones, it cannot exhibit a sustained therapeutic effect. Therefore, a problem exists where insulin must be administered repeatedly to be effective. Frequent insulin administration can cause severe pain and discomfort for patients. Thus, improvements in insulin use are needed in terms of patient compliance, safety, and convenience. Due to the high molecular weight of insulin, it is easily hydrolyzed by gastric acid, pepsin, and gastrointestinal tract (GIT), as well as the physical barriers of the small intestinal mucosal epithelium, making it difficult to administer polypeptide drugs, including insulin, orally. To overcome these barriers, many different studies have been conducted, and positive results have been achieved in improving the bioavailability of insulin [1,2,3]. These studies mainly include absorption enhancers such as sodium caprate and sodium N-[8-(2-hydroxybenzoyl)amino]caprylate (SANC) [4], protease inhibitors such as aprotinin, soybean trypsin inhibitor, and leucine. (leupeptin)[5], nanocarriers (such as polymers, lipids and inorganic nanoparticles) and microneedles and microcapsule-like protein drug delivery devices (such as RaniPill) TM Capsule[6]. These technologies have also been studied in clinical trials, but the bioavailability of oral insulin appears to be only 1-2%[6,7]. Clinical trials of oral insulin have not progressed to more in-depth studies, likely due to cost-effectiveness concerns. Oral insulin administration can overcome the degradation by gastric acid and pepsin using enteric-coated formulations. However, the small intestine still contains various pancreatic protein-metabolizing enzymes, the most important of which are trypsin and chymotrypsin. Only by overcoming the degradation by small intestinal proteases can the residence time of insulin molecules in the small intestinal environment be prolonged, thereby promoting absorption by the small intestinal epithelium. Although the addition of protease inhibitors and absorption enhancers promotes the absorption of insulin in the small intestine [8, 9], it is still difficult to overcome the protease degradation of insulin after it enters the bloodstream. The insulin molecule consists of two polypeptide chains, A and B, containing 21 and 30 amino acids respectively, linked by two disulfide bonds. Structurally, it is relatively stable against trypsin degradation.
[0010] The main protease that degrades insulin in the small intestinal microenvironment is chymotrypsin. Existing technologies to improve the stability of insulin molecules against protease degradation include D-amino acid substitution, PEG modification, and fatty acid acylation, but these methods still do not solve the problem of oral insulin administration. To address the shortcomings of existing technologies, this invention isolates and identifies a series of inhibitory peptides that inhibit chymotrypsin, and then forms hybrid peptides with insulin or its analogues to solve the stability problem of insulin molecules after protease degradation. Summary of the Invention This invention provides a hybrid peptide comprising insulin or an analogue thereof and a chymotrypsin inhibitory peptide, the two being linked by a linker peptide; wherein the insulin or analogue comprises a B-chain and an A-chain linked by two pairs of disulfide bonds; wherein the chymotrypsin inhibitory peptide is linked to the B-chain or A-chain of the insulin or analogue via the linker peptide. As shown in Figure 10, this invention provides five hybrid peptides formed by linking a chymotrypsin inhibitory peptide to the B-chain or A-chain of insulin or an analogue thereof. In one specific embodiment of the present invention, chymotrypsin inhibitory peptides were screened and identified by in vitro enzymatic methods. These peptides were selected from polypeptides having the following amino acid sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28. In one aspect of the invention, an insulin molecule or analogue thereof for synthesizing hybrid peptides is provided, the insulin or analogue thereof comprising an A-chain and a B-chain; wherein the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33; and the B-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40. Another aspect of the present invention provides a linker peptide that connects a chymotrypsin inhibitory peptide and an A-chain or B-chain of insulin or its analogues. The linker peptide contains three amino acid residues: Gly, Ser, and Pro, and its length is a peptide segment of one or more amino acid residues or a deletion thereof. This invention provides a hybrid peptide of insulin or an analogue thereof, containing a domain from the N-terminus to the C-terminus: (N-terminus)-chymotrypsin inhibitor-insulin B-chain---insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the B-chain of insulin or an analogue via a linker peptide; the “(N-terminus)-chymotrypsin inhibitor-insulin B-chain” is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin B-chain selected from polypeptides having the following amino acid sequences: SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33. In one embodiment, the hybrid peptide of insulin or its analogue provided by the present invention needs to be generated through the maturation and processing of its precursor protein. The precursor protein has a domain from the N-terminus to the C-terminus: (N-terminus)-chymotrypsin inhibitor-insulin B-chain-C-peptide-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the B-chain of insulin or its analogue via a linker peptide; the “(N-terminus)-chymotrypsin inhibitor-insulin B-chain” is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin B-chain selected from polypeptides having the following amino acid sequences: SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:71. The precursor protein requires three steps of treatment: cleavage with the protease Kex2, cleavage with the tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage. These treatments can be combined or performed sequentially. To obtain hybrid peptides of insulin or its analogues that do not contain two "RR"s at the C-terminus of the B-chain, treatment with carboxypeptidase B can be used; to obtain hybrid peptides of insulin or its analogues with an amidation-modified C-terminus, treatment with peptidylglycine α-amidyl monooxygenase can be used. In one specific embodiment, a precursor protein of an insulin or analogue hybrid peptide may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173, and SEQ ID NO:174. These precursor proteins require treatment with Kex2 enzyme digestion, TEV enzyme digestion, and nickel ion-induced chemical cleavage. To obtain an insulin or analogue hybrid peptide without two "RR"s at the C-terminus of the B-chain, further treatment with carboxypeptidase B may be used. Further treatment with peptidyl glycine α-amidyloxygenase may be used to obtain a hybrid peptide with an amidated C-terminus. For example, the hybrid peptide formed by fusing chymotrypsin inhibitory peptides CH57 (SEQ ID NO:4) and CH10 (SEQ ID NO:19) with the N-terminus of the B-chain of human insulin or analogue is as follows: The nucleotide coding sequences of these hybrid peptide precursor proteins can be selected from SEQ ID NO:175, SEQ ID NO:176, SEQ ID NO:177, SEQ ID NO:178, SEQ ID NO:179, SEQ ID NO:180, SEQ ID NO:181, SEQ ID NO:182, SEQ ID NO:183 and SEQ ID NO:184. This invention provides another hybrid peptide containing a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-chymotrypsin inhibitor---insulin A-chain-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the B-chain of insulin or its analogue via a linker peptide; the “(N-terminus)-insulin B-chain-chymotrypsin inhibitor” is a polypeptide formed by the fusion of the insulin B-chain and the chymotrypsin inhibitor, selected from polypeptides having the following amino acid sequences: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57 and SEQ ID NO:58; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33. In one embodiment, the hybrid peptide of insulin or its analogue provided by the present invention needs to be generated through the maturation and processing of its precursor protein. The precursor protein has a domain extending from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-chymotrypsin inhibitor-C-peptide-insulin A-chain-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the B-chain of insulin or its analogue via a linker peptide; the “(N-terminus)-insulin B-chain-chymotrypsin inhibitor” is a polypeptide formed by the fusion of the insulin B-chain and the chymotrypsin inhibitor, selected from polypeptides having the following amino acid sequences: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, and SEQ ID NO:58; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, and SEQ ID NO:33; and the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:72 and SEQ ID NO:73. The precursor protein requires processing with the protease Kex2. The treatment involves three steps: enzyme digestion, tobacco mosaic virus protease (TEV) digestion, and nickel ion-induced chemical cleavage. These steps can be combined or performed sequentially. To obtain hybrid peptides of insulin or its analogues without two "RR" ligations at the C-terminus of the B-chain, carboxypeptidase B can be used. To obtain hybrid peptides of insulin or its analogues with amidation modification at the C-terminus, peptidyl glycine α-amidyl monooxygenase can be used to further treat the hybrid peptides. In one specific embodiment, a precursor protein of an insulin or analogue hybrid peptide may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, and SEQ ID NO:196. These precursor proteins require treatment with protease Kex2, tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage. To obtain an insulin or analogue hybrid peptide without two “RR”s at the C-terminus of the B-chain, further treatment with carboxypeptidase B may be used. Further treatment with peptidyl glycine α-amidyl monooxygenase may be used to obtain a C-terminally amidated hybrid peptide. For example, the hybrid peptides formed by fusing chymotrypsin inhibitory peptides CH57 (SEQ ID NO:4) and CH10 (SEQ ID NO:19) with the C-terminus of the B-chain of human insulin or its analogues are as follows: The nucleotide coding sequences of these hybrid peptide precursor proteins can be selected from SEQ ID NO:197, SEQ ID NO:198, SEQ ID NO:199, SEQ ID NO:200, SEQ ID NO:201, SEQ ID NO:202, SEQ ID NO:203, SEQ ID NO:204, SEQ ID NO:205, SEQ ID NO:206, SEQ ID NO:207 and SEQ ID NO:208. This invention provides a hybrid peptide containing a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain--chymotrypsin inhibitor-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the A-chain of insulin or its analogue via a linker peptide, and the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "chymotrypsin inhibitor-insulin A-chain-(C-terminus)" is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62. In one embodiment, the hybrid peptide of insulin or its analogue provided by the present invention requires maturation processing of its precursor protein. The precursor protein has a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-chymotrypsin inhibitor-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the insulin or its analogue A-chain via a linker peptide; the B-chain of insulin or its analogue is selected from peptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40. The “chymotrypsin inhibitor-insulin A-chain-(C-terminus)” described in SEQ ID NO:40 is a peptide formed by the fusion of the chymotrypsin inhibitor and the insulin A-chain, selected from peptides having the following amino acid sequences: SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62; the C-peptide is selected from peptides having the following amino acid sequences: SEQ ID NO: 70. SEQ ID NO:71. The precursor protein requires three steps of treatment: cleavage with the protease Kex2, cleavage with the tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage. These treatments can be combined or performed sequentially. To obtain a hybrid peptide of insulin or its analogues without two "RR" ligations at the C-terminus of the B-chain, carboxypeptidase B treatment can be used. To obtain a hybrid peptide of insulin or its analogues with an amidation-modified C-terminus, peptidyl glycine α-amidyloxygenase treatment can be used. In one specific embodiment, a precursor protein of an insulin or analogue hybrid peptide may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216, SEQ ID NO:217, and SEQ ID NO:218. These precursor proteins require treatment with Kex2 enzyme digestion, TEV enzyme digestion, and nickel ion-induced chemical cleavage. To obtain an insulin or analogue hybrid peptide without two "RR"s at the C-terminus of the B-chain, further treatment with carboxypeptidase B may be used. Further treatment with peptidyl glycine α-amidyl monooxygenase may be used to obtain a hybrid peptide with an amidated C-terminus. For example, the hybrid peptide formed by fusing chymotrypsin inhibitory peptides CH57 (SEQ ID NO:4) and CH10 (SEQ ID NO:19) with the N-terminus of the A-chain of human insulin or analogue is as follows: The nucleotide coding sequences of these precursor proteins can be selected from SEQ ID NO:219, SEQ ID NO:220, SEQ ID NO:221, SEQ ID NO:222, SEQ ID NO:223, SEQ ID NO:224, SEQ ID NO:225, SEQ ID NO:226, SEQ ID NO:227 and SEQ ID NO:228. This invention provides another hybrid peptide containing a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain--insulin A-chain-chymotrypsin inhibitor-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the A-chain of insulin or its analogue via a linker peptide; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO: 35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; The “insulin A-chain-chymotrypsin inhibitory peptide-(C-terminus)” is a polypeptide formed by the fusion of insulin A-chain and chymotrypsin inhibitory peptide selected from polypeptides having the following amino acid sequences: SEQ ID NO:63, SEQ ID NO:64. In another embodiment, the hybrid peptide of insulin or its analogue provided by the present invention requires maturation processing of its precursor protein. The precursor protein has a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-insulin A-chain-chymotrypsin inhibitor-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor peptide is directly fused to the C-terminus of the insulin or its analogue A-chain via a linker peptide; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-(C-terminus)" is a polypeptide formed by the fusion of the insulin A-chain and the chymotrypsin inhibitor peptide, selected from polypeptides having the following amino acid sequences: SEQ ID NO:63, SEQ ID NO:64; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:71. The precursor protein undergoes three steps of treatment: cleavage with Kex2 proteinase, cleavage with TEV proteinase from tobacco mosaic virus, and nickel ion-induced chemical cleavage. These treatment methods can be combined or performed sequentially. To obtain hybrid peptides of insulin or its analogues without two "RR" at the C-terminus of the B-chain, carboxypeptidase B can be used for further treatment. To obtain hybrid peptides of insulin or its analogues with C-terminal amidation modification, peptidyl glycine α-amidyloxygenase can be used for further treatment of the hybrid peptides. In one specific embodiment, a precursor protein of an insulin or analogue hybrid peptide may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, and SEQ ID NO:238. These precursor proteins require treatment with Kex2 enzyme digestion, TEV enzyme digestion, and nickel ion-induced chemical cleavage. To obtain an insulin or analogue hybrid peptide without two "RR"s at the C-terminus of the B-chain, further treatment with carboxypeptidase B may be used. Further treatment with peptidyl glycine α-amidyl monooxygenase may be used to obtain a hybrid peptide with an amidated C-terminus. For example, the hybrid peptide formed by fusing chymotrypsin inhibitory peptides CH57 (SEQ ID NO:4) and CH10 (SEQ ID NO:19) with the C-terminus of the A-chain of human insulin or analogue is as follows: The nucleotide coding sequences of these precursor proteins can be selected from SEQ ID NO:239, SEQ ID NO:240, SEQ ID NO:241, SEQ ID NO:242, SEQ ID NO:243, SEQ ID NO:244, SEQ ID NO:245, SEQ ID NO:246, SEQ ID NO:247 and SEQ ID NO:248. This invention provides yet another hybrid peptide containing a domain extending from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus), wherein chymotrypsin inhibitor... The chymotrypsin inhibitory peptide directly forms a fusion peptide with the A-chain of insulin or its analogue; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitory peptide-A-chain-(C-terminus)" is a polypeptide formed by fusing a chymotrypsin inhibitory peptide in the middle of the insulin A-chain and is selected from polypeptides having the following amino acid sequences: SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68. In another embodiment, the present invention provides a hybrid peptide of insulin or its analogue, which requires maturation processing of its precursor protein. The precursor protein has a domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus), wherein the chymotrypsin inhibitor peptide directly forms a fusion peptide with the A-chain of insulin or its analogue; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus)" is a polypeptide formed by fusing the chymotrypsin inhibitor peptide in the middle of the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:71. The precursor protein undergoes three steps of treatment: cleavage with Kex2 proteinase, cleavage with TEV proteinase from tobacco mosaic virus, and nickel ion-induced chemical cleavage. These treatment methods can be combined or performed sequentially. To obtain a hybrid peptide of insulin or its analogues without two "RR" ligations at the C-terminus of the B-chain, carboxypeptidase B can be used for further treatment. To obtain a hybrid peptide of insulin or its analogues with an amidation-modified C-terminus, peptidyl glycine α-amidyl monooxygenase can be used to treat the hybrid peptide. In one specific embodiment, a precursor protein of an insulin or analogue hybrid peptide may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:255, SEQ ID NO:256, SEQ ID NO:257, and SEQ ID NO:258. These precursor proteins require treatment with Kex2 enzyme digestion, TEV enzyme digestion, and nickel ion-induced chemical cleavage. To obtain an insulin or analogue hybrid peptide without two "RR"s at the C-terminus of the B-chain, further treatment with carboxypeptidase B may be used. Further treatment with peptidyl glycine α-amidyl monooxygenase may be used to obtain a hybrid peptide with an amidated C-terminus. For example, the hybrid peptide formed by the direct fusion of chymotrypsin inhibitory peptides CH57 (SEQ ID NO:4) and CH10 (SEQ ID NO:19) with the A-chain of human insulin or analogue is as follows: The nucleotide coding sequences of these precursor proteins can be selected from SEQ ID NO:259, SEQ ID NO:260, SEQ ID NO:261, SEQ ID NO:262, SEQ ID NO:263, SEQ ID NO:264, SEQ ID NO:265, SEQ ID NO:266, SEQ ID NO:267 and SEQ ID NO:268. In one embodiment of the present invention, a method for heterologous biological preparation of a hybrid peptide containing a chymotrypsin inhibitory peptide and insulin or an analogue thereof is provided. The biological preparation process involves first synthesizing a precursor protein, followed by a series of protease digestion and chemically induced cleavage steps, and finally chromatographic purification. The precursor protein contains an N-terminus of a tobacco mosaic virus protease (TEV) cleavage site (ENLYFQ) as shown in SEQ ID NO:69, and the C-peptide between the B-chain and A-chain of the insulin molecule or its analogue is selected from peptides with the following sequences: SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, and SEQ ID NO:73. As shown in Figure 10, the precursor protein of the heterologous fusion expression hybrid peptide in this invention contains two proteases, Kex2 and two TEV cleavage sites. Kex2 cleaves the signal peptide that guides the secretion and expression of the precursor protein and the "RR" peptide bond (the peptide bond after the "RR" double basic amino acid residue) between the B-chain of insulin or its analogue and the linker peptide at the C-terminus. TEV cleaves and processes the precursor protein of the hybrid peptide to form a mature hybrid peptide. Then, it is subjected to nickel ion-induced chemical cleavage and / or treatment with carboxypeptidase B and peptidyl glycine α-amidyl monooxygenase, or no treatment. In one embodiment of the present invention, a hybrid peptide comprising insulin or an analogue thereof and a chymotrypsin inhibitory peptide is provided for the use in the treatment of type 1 and type 2 diabetes. In another embodiment of the present invention, the hybrid peptide is provided for administration via subcutaneous injection and oral administration in the treatment of type 1 and type 2 diabetes. Beneficial technical effects: This invention can improve the stability of insulin molecules by fusing chymotrypsin inhibitory peptides with insulin or its analogues, thereby promoting oral administration, improving patient compliance and reducing side effects, and has beneficial economic value. To facilitate understanding and practice of the invention, one or more preferred embodiments thereof are now described by way of example only with reference to the accompanying drawings. Attached Figure Description Various features of the invention are specific in the claims. A better understanding of the features and advantages of the invention will be obtained by referring to the following detailed description, which utilizes the principles of the invention in the illustrative embodiments, and the accompanying drawings include: Figure 1. Michaelis constant K of chymotrypsin m The determination of the Michaelis constant K for the hydrolysis of AAPFpNA by chymotrypsin was obtained by plotting the concentration of the substrate AAPFpNA against the initial velocity V0 using Prism software. m Values. The experiment was set up with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 2. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH5, CH11, CH18, and CH25) were added to investigate their inhibitory effects on chymotrypsin, and the concentrations at which they produced 50% inhibition (IC50) were determined. 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 3. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH33, CH34, and CH35) were added to investigate their inhibitory effects on chymotrypsin, and the concentrations at which they produced 50% inhibition (IC50) were determined. 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 4. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH26 and CH51) were added to investigate their inhibitory effects on chymotrypsin, and the concentration at which they produced 50% inhibition (IC50) was determined. 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 5. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH10, CH54, CH55, and CH57) were added to investigate their inhibitory effects on chymotrypsin, and the concentrations at which they produced 50% inhibition (IC50) were determined. 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 6. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH10, CH60, CH61, and CH62) were added to investigate their inhibitory effects on chymotrypsin, and the concentrations at which they produced 50% inhibition (IC50) were determined. 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 7. Determination of the inhibitory activity of chymotrypsin inhibitory peptides. Different concentrations of chymotrypsin inhibitory peptides (CH65, CH69, CH70, and CH71) were added to investigate their inhibitory effects on chymotrypsin, and their ability to produce 50% inhibition of enzyme activity was determined. Concentration at which action is achieved (IC50) 50 The experiment was conducted with three replicates, and the calculated values are expressed as "mean ± standard deviation". Figure 8. Schematic diagram of the methanol yeast expression vector pDeut-Aox1-ScKex2 contains two promoters, AOX1 and DAS2, with different methanol-induced expression strengths. The relatively weaker promoter, DAS2, initiates the expression of the yeast protease Kex2. Figure 9. Gene editing Cas9 / gRNA expression vector targeting the AOX1 gene in yeast. Figure 10. Precursor protein expression and maturation cleavage process of insulin or its analogue hybrid peptides. The αMF signal peptide guides the precursor protein to target the endoplasmic reticulum. In the endoplasmic reticulum, the signal peptide is cleaved by the signal peptide to remove the signal peptide, and the precursor protein transporter is trans-Golgi apparatus. The precursor region of αMF and the "RR" post-peptide bond at the C-terminus of the B-chain are cleaved by the protease Kex2. Then, it is packaged and secreted into the extracellular space. After further cleavage by the protease TEV, carboxypeptidase B, and nickel ion-induced cleavage, the insulin analogue hybrid peptide is obtained. Detailed Implementation Natural protease inhibitors have been used as additives in experimental studies to protect insulin molecules from protease degradation. Among these polypeptide protease inhibitors, one inhibitor selected from the soybean trypsin inhibitor BBI family contains two active loops that inhibit human trypsin and chymotrypsin; this protease inhibitor has been disclosed in PCT patents WO2014191545, WO2019239405, and WO2017161184. Compared to BBI peptide inhibitors, Sunflower Trypsin Inhibitor-1 (SFTI-1) is a head-to-tail cyclic peptide isolated from sunflower seeds, containing only 14 amino acid residues. PCT patent publication number WO2020023386 also describes its potential use as a protease inhibitor, i.e., an oral pharmaceutical component for the treatment of diabetes. SFTI-1 forms a rigid structure containing two short β-sheets, an intramolecular disulfide bond, and head-to-tail cyclication. Despite its structurally stable cyclic structure, SFTI-1 is difficult to directly couple with therapeutic peptides and can only be used as an additive. However, SFTI-1 only exhibits antitrypsin activity and not antichymotrypsin activity; therefore, SFTI-1 cannot act as a chymotrypsin inhibitor to protect against the degradation of insulin molecules by chymotrypsin. The P1 site of serine protease inhibitory peptides determines the specificity of different serine proteases. The P1 sites for chymotrypsin are Tyr and Phe. Only a few studies have reported that peptide inhibitors derived from the BBI family polypeptide backbone have antichymotrypsin activity [11-14], but the inhibitory activity is weak; and the active peptides disclosed in the literature that inhibit chymotrypsin are only used for their functional application as chymotrypsin inhibitors. Based on the core molecular backbone of the trypsin inhibitor SFTI-1, this invention alters the protease specificity of the inhibitory peptide molecular backbone by replacing the P1 site. Further optimization experiments were conducted, involving the replacement of different recognition sites and evaluation of inhibitory activity. The resulting polypeptide molecular backbone for inhibiting chymotrypsin is as follows: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, and SEQ ID NO:28. The chymotrypsin inhibitory peptide provided by the present invention directly forms a hybrid peptide fused with a bioactive peptide, which changes the situation where the additive used to inhibit chymotrypsin only protects the active polypeptide from partial degradation by chymotrypsin at the release site, and can also enter the blood circulation along with the active polypeptide such as insulin, thus continuously protecting its anti-chymotrypsin degradation effect. Insulin molecules themselves have good resistance to trypsin. The most important metabolic enzyme in the small intestine is chymotrypsin, which accounts for 9% of the total protein secreted by the pancreas
[0015] . In this invention, chymotrypsin inhibitory peptides are used to directly form hybrid peptides with insulin or its analogue molecules. The hybrid peptides formed are protected from degradation by proteases throughout the entire process from the microenvironment of the small intestine to entering the blood circulation and exerting their drug effect. Peptide Synthesis: The peptides of the present invention can be prepared by various methods. For example, the peptides can be synthesized by commonly used solid-phase synthesis methods, such as methods involving t-BOC or FMOC protection of α-amino groups known in the art. Here, amino acids are added sequentially to a continuously growing amino acid chain. Solid-phase synthesis methods are particularly suitable for synthesizing peptides or relatively short peptides in large-scale production. Determination of enzyme inhibitory activity: The inhibition constant of the synthesized active polypeptide protease inhibitor (molecular backbone) was determined. The inhibitory activity of porcine α-chymotrypsin was determined by competitive binding using the chromogenic substrate N-succinyl-Ala-Ala-Pro-Phe-p-nitroaniline (AAPFpNA). Experiments related to the inhibitory activity against porcine α-chymotrypsin were performed in 20 mM CaCl2, 50 mM Tris-HCl buffer (pH 7.8). Peptide concentration was determined using the optical density (OD) at 280 nm. The Michaelis constant (Km) of the enzyme hydrolyzing the substrate was calculated from the initial hydrolysis rate at 405 nm. The absorbance of the substrate was measured at 405 nm after complete hydrolysis. All data were processed using nonlinear regression. Insulin analogues: The chymotrypsin inhibitor obtained in this invention can widely form antichymotrypsin with insulin analogs. Degraded hybrid peptides improve their stability and in vitro and in vivo biological activity. Insulin or its analogues are not limited to the insulin or its analogues selected as examples in this invention, but can be analogues whose B-chain has one or more amino acid residues replaced, for example, SEQ ID NO:74(FVQQHLCGSHLVEALYLVCGERGFFYTPKT), SEQ ID NO:75(FVNQHLCGSHLVEALYLVCGERGFFYTPKQ), SEQ ID NO:76(FVNQHLCGSHLVEALYLVCGERGFFYTPKE), SEQ ID NO:77(FVQQHLCGSHLVEALYLVCGERGFFYTPKE), SEQ ID NO:78(FVNQHLCGSHLVEALYLVCGERGFFYTDPT), SEQ ID NO:79(FVNQHLCGSHLVQALYLVCGERGFFYTPKT), SEQ ID NO:80(FVNQHLCGSHLVEALALVCGERGFFYTPKT), SEQ ID NO:79(FVNQHLCGSHLVQALYLVCGERGFFYTPKT), SEQ ID NO:80(FVNQHLCGSHLVEALALVCGERGFFYTPKT), SEQ ID NO:79(FVNQHLCGSHLVQALYLVCGERGFFYTPKT), SEQ ID NO:7 ... SEQ ID NO:81(FVNQHLCGSHLVEALYLVCGEEGFFYTPKT), SEQ ID NO:82(FVNQHLCGSHLVEALYLVCGEEGFFYTLPT), SEQ ID NO:83(FVNQHLCGSHLVEALYLVCGERGFFYTVPT), SEQ ID NO:84(FVNQHLCGSHLVEALYLVCGERGFFYTAPT); or analogs that replace one or more amino acid residues in the A-chain, for example, SEQ ID NO:85(GIVEQCCTSICSLYQLENYCN), SEQ ID NO:86(GIVEQCCTSICSLYQLENYCS), SEQ ID NO:87(GIVEQCCHSICSLYQLENYCN), SEQ ID NO:88(GIVEQCCWSICSLYQLENYCN), SEQ ID NO:89(GIVEQCCMSICSLYQLENYCN). Protease cleavage and maturation of hybrid peptide precursor proteins: The hybrid peptide of the present invention utilizes eukaryotic cells for heterologous secretory expression of its precursor protein, wherein the precursor protein is cleaved by the protease Kex2 in the expression host cell to promote its secretory expression; then, the protease TEV of tobacco mosaic virus has broad substrate characteristics
[0016] , and the N-terminal fusion peptide (ENLYFQ, SEQ ID NO:69) of the secreted precursor protein (insulin analog) B-chain and A-chain is cleaved and modified to release the correct B-chain or A-chain; at the same time, a nickel ion-induced cleavage peptide (G↓SRHW) (SEQ ID NO:72, SEQ ID NO:73) is introduced at the C-terminus of the precursor protein (insulin analog) B-chain and A-chain
[0017] . Furthermore, treatment with or without carboxypeptidase B can yield hybrid peptides with or without the two basic amino acid "RR" at the C-terminus, respectively. When the C-terminus of the B-chain or A-chain contains a nickel ion-induced cleavage peptide (G↓SRHW), nickel ion-mediated cleavage will result in the peptide being cleaved at its C-terminus. By fusing a glycine (Gly) residue to the C-terminus, a recombinant amidase can be used to treat the mature B-chain or A-chain, resulting in an amidation protective modification at the C-terminus. C-peptide: Also known as C-peptide, the natural C-peptide is a single-chain polypeptide composed of 31 amino acids, linking the B-chain and A-chain in the proinsulin molecule. This invention describes a polypeptide linking the B-chain and A-chain in the precursor protein of insulin or its analogue hybrid peptides, which may have the same or different amino acid structure as the natural C-peptide. definition: Unless otherwise defined herein, all terms used herein have the same meaning as understood by one of ordinary skill in the art. The following definitions are provided to offer clarity regarding the terminology used in the specification and claims describing the invention. The singular forms “a”, “an”, and “the” include the plural unless the context clearly indicates otherwise. As is clear to those skilled in the art, the polypeptide sequences disclosed herein are displayed from left to right, with the left end of the sequence representing the N-terminus of the polypeptide and the right end representing the C-terminus of the polypeptide. The term "hybrid peptide" as used in this invention refers to two peptide segments linked by natural peptide bonds, which can be prepared by solid-phase synthesis or biological expression. As used herein, the term "connecting peptide" broadly refers to a glycine, serine, or proline-rich peptide that facilitates the formation of a transition structure, enabling the linking of two polypeptides together to form a single chemical structure. In this invention, the concept also applies to C-peptides, which function to connect B-chains and A-chains to form precursor proteins. As used herein, the term "protease inhibitor" refers to a polypeptide molecule that inhibits the function of a protease. In this invention, protease inhibitors inhibit chymotrypsin, found in the mammalian gastrointestinal tract, and chymotrypsin-like proteases in the bloodstream. Non-patent literature: 1. Pinelo R, Roque L, Reis CP. Oral insulin delivery: utopia, currently possible or a near reality? Ther Deliv.2021,12(6):477-488. 2.Iyer G,Dyawanapelly S,Jain R,Dandekar P.An overview of oral insulin delivery strategies(OIDS).Int J Biol Macromol.2022,208:565-585. 3. Gedawy A, Martinez J, Al-Salami H, Dass CR. Oral insulin delivery: existing barriers and current counter-strategies. J Pharm Pharmacol. 2018, 70(2): 197-213. 4.Twarog C, Fattah S, Heade J, et al. Intestinal permeation enhancers for oral delivery of macromolecules: a comparison between salcaprozate sodium(SNAC)and sodium caprate(C10).Pharmaceutics 11,E78(2019). 5.Liu H, Tang R, Pan WS, et al. Potential utility of various protease inhibitors for improving the intestinal absorption of insulin in rats. J Pharm Pharmacol, 2003, 55(11):1523–1529. 6.Drucker DJ.Advances in oral peptide therapeutics.Nat Rev Drug Discov,2020,19(4):277–289. 7.Zijlstra E,Heinemann L,Plum-Morschel L.Oral insulin reloaded:astructured approach.J Diabetes Sci Technol,2014,8(3):458–465. 8.Eldor R,Arbit E,Corcos A,Kidron,M.Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes:a pilot study.PLOS ONE,2013,8:e59524. 9.Zhang Y,Zhou W,Shen L,et al.Safety,Pharmacokinetics,and Pharmacodynamics of Oral Insulin Administration in Healthy Subjects:A Randomized,Double-Blind,Phase 1 Trial.Clin Pharmacol Drug Dev.2022,11(5):606-614. 10.Schilling RJ,Mitra AK.Degradation of insulin by trypsin and alpha-chymotrypsin.Pharm Res.1991,8(6):721-727. 11.McBride JD,Brauer AB,Nievo M,Leatherbarrow RJ.The role of threonine in the P2 position of Bowman-Birk proteinase inhibitors:studies on P2 variation in cyclic peptides encompassing the reactive site loop.J Mol Biol,1998,282:447-458. 12.McBride JD,Freeman N,Domingo GJ,Leatherbarrow RJ.Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library.J Mol Biol,1996,259:819-827. 13.McBride JD,Freeman HN,Leatherbarrow RJ.Identification of chymotrypsin inhibitors from a second-generation template assisted combinatorial peptide library.J Pept Sci,2000,6:446-452. 14. A,Debowski D,Lesner A,Wysocka M,Rolka K.Introduction of non-natural amino acid residues into the substrate-specific P1 position of trypsin inhibitor SFTI-1 yields potent chymotrypsin and cathepsin G inhibitors.Bioorg Med Chem,2009,17(9):3302-3307. 15. Whitcomb DC, Lowe ME. Human pancreatic digestive enzymes. Dig Dis Sci, 2007, 52(1):1-17. 16. Kapust RB, J,Copeland TD,Waugh DS.The P1'specificity of tobacco etch virus protease.Biochem Biophys Res Commun,2002,294(5):949-55. 17.Dang B, Mravic M, Hu H, et al. SNAC-tag for sequence-specific chemical protein cleavage. Nat Methods, 2019, 16(4): 319-322. The following examples are cited to illustrate the implementation of the present invention and are only for a better understanding of the present invention, but should not be construed as limiting the scope or spirit of the present invention. Example Example 1: Solid-phase synthesis of polypeptides According to the sequence of each amino acid residue of the peptide, the peptide was synthesized one by one from the C-terminus to the N-terminus using the fluorene methoxycarbonyl (Fmoc) solid-phase chemical synthesis method. After the synthesis of the linear peptide protected by the amino acid side chain was completed, the linear peptide was cleaved from the resin, the protecting groups of the amino acid residues in the linear peptide were removed, and then intramolecular oxidative cyclization of thiol groups was performed to form disulfide bonds. Finally, the target peptide was purified by high-performance liquid chromatography reversed-phase C18 column chromatography. I. Raw Materials (1) Resins: Fmoc-L-alanine-Wang resin, Fmoc-N-(2,2,4,6,7-pentamethylbenzodihydrofuran-5-sulfonyl)-L-arginine-Wang resin, Fmoc-N-triphenylmethyl-L-asparagine-Wang resin, Fmoc-Asn(Trt)-Wang resin, Fmoc-O-tert-butyl-L-aspartic acid-Wang resin, Fmoc-L-glycine-Wang resin, Fmoc-L-phenylalanine-Wang resin, Fmoc-Pro-Wang resin resin), Fmoc-O-tert-butyl-L-tyrosine-Wang resin (Fmoc-Tyr(tBu)-Wang resin). (3) Reagents: piperidine, DMF (N,N-dimethylformamide), DCM (dichloromethane), 4-Picoline (4-methylpyridine), DIEA (diisopropylethylamine), HATU (2-(7-azabenzotriazole)-N,N,N',N'-tetramethylurea hexafluorophosphate), HOBT (1-hydroxybenzotriazole), TBTU (O-benzotriazole-N,N,N',N'-tetramethylurea tetrafluoroboric acid), DIC (diisopropylcarbodiimide), TFA (trifluoroacetic acid), EDT (1,2-ethylenedithiol), TIPS (triisopropylsilane), TA (aniline sulfide), phenol, diethyl ether, DMSO (dimethyl sulfoxide), and purified water. II. Synthesis Method SEQ ID NO:1(Gly-Arg-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro-Asp) (1) Weigh Fmoc-Asp(OtBu)-Wang resin, put it into a glass reaction column, add DCM to swell for 30 min, and remove DCM under reduced pressure. (2) Wash the resin three times with DMF, add piperidine / DMF (1:4, v / v) solution and react for 20 min to remove the protecting group Fmoc, remove the solution under reduced pressure, and wash with DMF six times. (3) Weigh out the second amino acid Fmoc-Pro-OH and TBTU respectively and add them to the resin. Dissolve DMF and add DIEA. React for 30 minutes. Take the resin and perform a Kaiser Test to check the reaction. When the solution is bright yellow and the resin is yellow, it indicates that the reaction is complete. Remove the solvent under reduced pressure. (4) Repeat steps (2) and (3) to finally obtain a peptide with a protecting group, namely Fmoc-Gly-Arg(Pbf)-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Pro-Asp(OtBu)-Wang resin. Remove Fmoc, then wash three times each with DMF, DCM and methanol, and dry the resin. (5) Add lysis buffer (TFA, EDT, TA, phenol and pure water mixed in a certain proportion) to remove resin and amino acid side chain protecting groups, filter with sand core, add ether to the filtrate to precipitate, centrifuge, wash the solid 3 times, and dry. (6) Dissolve in H2O / acetonitrile (9:1, v / v), increase the volume to 100 mL, add dilute ammonia to adjust to alkaline (pH≈8), take a small sample to test the activity of thiol groups. Yellow indicates the presence of thiol groups. Add 2-3 drops of hydrogen peroxide, react for 5-10 min, and test again. If the solution is transparent, it indicates complete oxidation (more than 90%). Add glacial acetic acid to adjust to acidic (pH≈6). Its chemical structure is characterized by mass spectrometry. After the result is correct, the target peptide is purified by high performance liquid chromatography reversed-phase C18 column chromatography. (7) The measured molecular weight of SEQ ID NO:1 (CH54) is 1550.4 Da ([M+2H]). 2+ =776.2). SEQ ID NO:2(Gly-Arg-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro-Asp) SEQ ID NO:2 uses Fmoc-Asp(OtBu)-Wang resin as the starting material and synthesizes it according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the polypeptide sequence are added sequentially, and then a peptide with a protecting group is synthesized. Fmoc-Gly-Arg(Pbf)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Pro-Asp(OtBu)-Wang resin, remove Fmoc, then add lysis buffer to remove resin and amino acid side chains. Protective groups were removed and oxidized to form disulfide bonds. Finally, the target peptide SEQ ID NO:2 (CH55) was separated and purified, with a measured molecular weight of 1566.4 Da ([M+2H)). 2+ =784.2). SEQ ID NO:3(Gly-Arg-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro) SEQ ID NO:3 uses Fmoc-Pro-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Arg(Pbf)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Pro-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:3 (CH56) is separated and purified, with a measured molecular weight of 1452.2 Da ([M+2H)). 2+ =727.1). SEQ ID NO:4(Gly-Arg-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:4 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Arg(Pbf)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:4 (CH57) is separated and purified, with a measured molecular weight of 1354.2 Da ([M+2H)). 2+ =678.1). SEQ ID NO:5(Arg-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:5 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Arg(Pbf)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:5 (CH58) is separated and purified, with a measured molecular weight of 1297.0 Da ([M+2H)). 2+ =649.5). SEQ ID NO:6(Gly-Thr-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Ile-Cys-Asn-Pro-Asn) SEQ ID NO:6 uses Fmoc-Asn(Trt)-Wang resin as the starting material and synthesizes it according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the polypeptide sequence are added sequentially, followed by the synthesis of a peptide containing [specific amino acid sequence]. The peptide with the protecting group, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn-Pro-Asn(Trt)-Wang resin, was deprotected by removing Fmoc, and then lysis buffer was added to remove the resin and amino acid side chain protecting groups, and oxidized to form disulfide bonds. Finally, the target peptide SEQ ID NO:6 (CH59) was separated and purified, with a measured molecular weight of 1461.0 Da ([M+2H)). 2+ =731.5). SEQ ID NO:7(Gly-Thr-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Asn-Pro-Asn) SEQ ID NO:7 uses Fmoc-Asn(Trt)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Pro-Asn(Trt)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:7 (CH60) is separated and purified, with a measured molecular weight of 1477.2 Da ([M+2H)). 2+ =739.6). SEQ ID NO:8(Gly-Thr-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Asn-Pro) SEQ ID NO:8 uses Fmoc-Pro-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Pro-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:8 (CH61) is separated and purified, with a measured molecular weight of 1363.2 Da ([M+2H)). 2+ =682.6). SEQ ID NO:9(Gly-Thr-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Asn) SEQ ID NO:9 uses Fmoc-Asn(Trt)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:9 (CH62) is separated and purified. Its actual measurement... The molecular weight is 1266.0 Da ([M+2H]). 2+ =634.0). SEQ ID NO:10(Thr-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Asn) SEQ ID NO:10 uses Fmoc-Asn(Trt)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Thr(tBu)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:10 (CH63) is separated and purified, with a measured molecular weight of 1209.3 Da ([MH)). - =1208.3). SEQ ID NO: 11 (Lys-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:11 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Lys(Boc)-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:11 (CH64) is separated and purified, with a measured molecular weight of 1269.2 Da ([M+2H)). 2+ =635.6). SEQ ID NO:12 (Cys-Gly-Arg-Ala-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro-Asp) SEQ ID NO:12 uses Fmoc-Asp(OtBu)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Gly-Arg(Pbf)-Ala-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Pro-Asp(OtBu)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:12 (CH65) is separated and purified, with a measured molecular weight of 1637.2 Da ([M+2H)). 2+ =819.6). SEQ ID NO:13(Cys-Gly-Arg-Ala-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe-Pro) SEQ ID NO:13 uses Fmoc-Pro-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Gly-Arg(Pbf)-Ala-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Pro-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:13 (CH66) is obtained after separation and purification, with a measured molecular weight of 1523.2 Da ([M+2H)). 2+ =762.6). SEQ ID NO:14(Cys-Gly-Arg-Ala-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:14 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Gly-Arg(Pbf)-Ala-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:14 (CH67) is obtained after separation and purification, with a measured molecular weight of 1425.2 Da ([M+2H)). 2+ =713.6). SEQ ID NO:15(Cys-Gly-Arg-Ala-Abu-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:15 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Gly-Arg(Pbf)-Ala-Abu-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:15 (CH68) is separated and purified, with a measured molecular weight of 1439.2 Da ([M+2H)). 2+ =720.6). SEQ ID NO:16(Cys-Lys-Arg-Ala-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:16 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the polypeptide sequence are added sequentially to synthesize a peptide with a protecting group, namely Fmoc-Cys(Trt)-Lys(Boc)-Arg(Pbf)-Ala-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-C The ys(Trt)-Phe-Wang resin was de-Fmoc removed, and then lysis buffer was added to remove the resin and amino acid side chain protecting groups, and oxidized to form disulfide bonds. Finally, the target peptide SEQ ID NO:16(CH69) was separated and purified, with a measured molecular weight of 1496.2 Da([M+2H)). 2+ =749.1). SEQ ID NO:17(Cys-Glu-Arg-Ala-Thr-Tyr-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:17 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Glu(OtBu)-Arg(Pbf)-Ala-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:17 (CH70) is separated and purified, with a measured molecular weight of 1497.2 Da ([M+2H)). 2+ =749.6). SEQ ID NO:18(Cys-Gly-Arg-Ala-Thr-Phe-Ser-Ile-Pro-Pro-Ile-Cys-Phe) SEQ ID NO:18 uses Fmoc-Phe-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Cys(Trt)-Gly-Arg(Pbf)-Ala-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Phe-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:18 (CH71) is separated and purified, with a measured molecular weight of 1409.2 Da ([M+2H)). 2+ =705.6). SEQ ID NO:19(Phe-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Gln-Cys-Tyr-Gly) SEQ ID NO:19 uses Fmoc-Gly-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Phe-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Gly-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:19 (CH10) is separated and purified, with a measured molecular weight of 1375.55 Da ([M+Na)). + =1398.55). SEQ ID NO:20(Phe-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Gln-Cys-Tyr-Gly) SEQ ID NO:20 uses Fmoc-Gly-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid raw materials corresponding to the peptide sequence are added sequentially to synthesize a peptide with a protecting group, namely Fmoc-Phe-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Gly-Wang resin. Fmoc is removed, and then lysis buffer is added to remove the resin and amino acid side chain protecting groups and oxidize to form disulfide bonds. Finally, the target peptide SEQ ID NO:20 (CH5) is separated and purified, and its measured molecular weight is 1360.02 Da ([M+K+H]2+=700.01). SEQ ID NO:21 (Ser-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Gln-Cys-Tyr-Gly) SEQ ID NO:21 uses Fmoc-Gly-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Ser(tBu)-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Gly-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:21 (CH11) is obtained after separation and purification, with a measured molecular weight of 1300.55 Da ([M+H)). + ). SEQ ID NO:22 (Ala-Cys-Thr-Tyr-Ser-Ile-Pro-Ala-Lys-Cys-Phe) SEQ ID NO:22 was synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence were added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Ala-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Ala-Lys(Boc)-Cys(Trt)-Phe-Wang resin. Fmoc was removed, and then lysis buffer was added to remove the resin and amino acid side chain protecting groups, followed by oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:22 (CH18) was separated and purified, with a measured molecular weight of 1200.80 Da ([M+2H)). 2+ =601.40). SEQ ID NO:23 (Gly-Thr-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Ile-Cys-Asn-Pro-Asn) SEQ ID NO:23 uses Fmoc-Asn(Trt)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Pro-Asn(Trt)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:23 (CH25) is obtained after separation and purification, with a measured molecular weight of 1461.00 Da ([M+2H)). 2+ =731.50). SEQ ID NO:24 (Gly-Thr-Cys-Thr-Phe-Ser-Ile-Pro-Pro-Ile-Cys-Asn) SEQ ID NO:24 uses Fmoc-Asn(Trt)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Gly-Thr(tBu)-Cys(Trt)-Thr(tBu)-Phe-Ser(tBu)-Ile-Pro-Pro-Ile-Cys(Trt)-Asn(Trt)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:24 (CH26) is separated and purified, with a measured molecular weight of 1249.50 Da ([M+Na)). + =1272.50). SEQ ID NO:25 (Phe-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Gln-Cys-Tyr) SEQ ID NO:25 uses Fmoc-Tyr(tBu)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Phe-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:25 (CH33) is obtained after separation and purification, with a measured molecular weight of 1318.80 Da ([M+2H)). 2+ =660.40). SEQ ID NO:26 (Phe-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Gln-Cys-Tyr-Ala) SEQ ID NO:26 uses Fmoc-Ala-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Phe-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Ala-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:26 (CH34) is obtained after separation and purification, with a measured molecular weight of 1390.80 Da ([M+2H)). 2+ =696.40). SEQ ID NO:27 (Phe-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Gln-Cys-Arg) SEQ ID NO:27 uses Fmoc-Arg(Pbf)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Phe-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Arg(Pbf)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:27 (CH35) is obtained after separation and purification, with a measured molecular weight of 1312.20 Da ([M+2H)). 2+ =657.10). SEQ ID NO:28 (Pro-Cys-Thr-Tyr-Ser-Ile-Pro-Pro-Gln-Cys-Tyr) SEQ ID NO:28 uses Fmoc-Tyr(tBu)-Wang resin as the starting material and is synthesized according to the method described in SEQ ID NO:1. First, amino acid precursors corresponding to the peptide sequence are added sequentially to synthesize a peptide with protecting groups, namely Fmoc-Pro-Cys(Trt)-Thr(tBu)-Tyr(tBu)-Ser(tBu)-Ile-Pro-Pro-Gln(Trt)-Cys(Trt)-Tyr(tBu)-Wang resin. Fmoc is then removed, followed by the addition of lysis buffer to remove the resin and amino acid side chain protecting groups, and oxidation to form disulfide bonds. Finally, the target peptide SEQ ID NO:28 (CH51) is obtained after separation and purification, with a measured molecular weight of 1268.80 Da ([M+2H)). 2+ =635.40). Example 2: Design and Inhibitory Activity Evaluation of Peptide Molecules that Inhibit Chymotrypsin Michaelis constant K m Determination of value: (1) Add 198 μL of 20 mM CaCl2 and 50 mM Tris-HCl buffer (pH 7.8) to a 96-well plate and preheat at 37°C for 15 min. Then add 2 μL of substrate pNA (prepared with DMSO) at different concentrations, mix at 500 rpm for 1 min, incubate at 37°C for 20 min, and measure OD. 405nmThe absorbance values were calculated. In a 200 μL reaction system, the final concentrations of pNA were 0, 0.025, 0.05, 0.075, 0.1, 0.125, 0.15, 0.25, and 0.3 mM. Three replicates were prepared for each concentration, and the absorbance was compared with the OD value based on the pNA concentration. 405nm Plot the values to obtain the standard curve. (2) Add 190 μL of 20 mM CaCl2, 50 mM Tris-HCl buffer (pH 7.8) and 8 μL of 0.75 μM chymotrypsin to a 96-well plate, and preheat at 37°C for 5 min. Then add 2 μL of substrate AAPFpNA (prepared in DMSO) at different concentrations, mix at 500 rpm for 1 min, and incubate at 37°C for 20 min. Measure the OD. 405 nm The absorbance values were measured. In a 200 μL reaction system, the final concentrations of AAPFpNA were 0, 0.125, 0.25, 0.285, 0.33, 0.4, and 0.5 mM. Three replicates were prepared for each concentration, and the absorbance was measured over time. 405nm Plot the values to obtain the corresponding curve. Divide the slope of the curve by the slope of the standard curve and the enzyme concentration to obtain the initial velocity V0 (mM / (min*mM protein)). Using Prism software, plot the initial velocity V0 against the concentration of the substrate AAPFpNA to obtain the Michaelis constant Km value for the hydrolysis of AAPFpNA by chymotrypsin. Suppression constant K i Determination of value: (1) Add different concentrations of chymotrypsin inhibitory peptide (CHs) backbone, 20 mM CaCl2, and 50 mM Tris-HCl buffer (pH 7.8) to a pre-chilled 96-well plate, totaling 190 μL. Preheat at 37°C for 5 min (centrifuge at 500 rpm for 1 min, then let stand for 4 min). Add 8 μL of 750 nM chymotrypsin and incubate at 37°C for 10 min (centrifuge at 500 rpm for 1 min, then let stand for 9 min). Add 2 μL of 50 mM substrate AAPFpNA, mix at 500 rpm for 1 min, and incubate at 37°C for 90 min. Measure the OD. 405nm The absorbance value was recorded. Three replicates were performed for each concentration. The blank control consisted of only buffer and substrate, and the absorbance value was used as the minimum absorbance (Min OD). 405nm The negative control consists of only buffer, enzyme, and substrate, and is used as the maximum absorbance (Max OD). 405nm ). (2) In a 200 μL reaction system, the final concentration of chymotrypsin is about 30 nM and the final concentration of AAPFpNA is about 0.5 mM. (3) Data statistics Remaining enzyme activity (%) = (1 - (Max OD)405nm -Sample OD 405nm ) / (Max OD 405nm -Min OD 405nm ))*100 By plotting substrate concentration against residual enzyme activity, the half-maximal inhibitory concentration (IC50) of the CHs backbone against chymotrypsin was determined. 50 Then substitute it into formula K. i =IC 50 / (1+S / Km)(S、IC 50 The inhibitory constant K for the CHs backbone inhibiting chymotrypsin can be obtained by considering K and Km as substrate concentration, half-maximal inhibitory concentration, and Michaelis constant, respectively. i . result: OD was determined by measuring the pNA produced by the catalytic hydrolysis of a certain concentration of chymotrypsin using different AAPF pNA concentrations. 405nm The absorbance value was used as a reference to a standard curve. Using Prism software, a graph was plotted against the initial velocity V0 with the concentration of the substrate AAPFpNA, thus obtaining the Michaelis constant K for the hydrolysis of AAPFpNA by chymotrypsin. m The value is 0.38mM(R) 2 =0.9988)(Figure 1). Most natural Bowman-Birk family protease inhibitors (BBIs) contain two independent inhibitory sites, inhibiting trypsin and chymotrypsin respectively. Soybean BBIs consist of 71 amino acid residues linked by seven disulfide bonds. One site inhibits trypsin at Lys16-Ser17, and the other inhibits chymotrypsin at Leu43-Ser44. It forms a 1:1 complex with trypsin or chymotrypsin and a ternary complex with both enzymes. This naturally occurring BBI structure exhibits weak protease inhibitory activity. Literature reports [McBride JD, Freeman N, Domingo GJ, Leatherbarrow RJ. Selection of chymotrypsin inhibitors from a conformationally-constrained combinatorial peptide library. J Mol Biol, 1996, 259:819-827.] that a single-inhibitory cyclic peptide linked by disulfide bonds can be obtained by simplifying the BBI structure. This invention combines the specificity of the chymotrypsin P1 site (specifically recognizing Tyr and Phe) with the conservation of P1' and P3' sites to design and synthesize a series of polypeptides (Table 1) cyclized with disulfide bonds and possessing a core structure of "CTYSIPPQC". In vitro inhibitory activity assays revealed two polypeptides, CH10 and CH5, with high inhibitory activity and IC5 values of [missing information]. 50 The values were 0.06 μM and 0.19 μM, respectively (Table 2), confirming that the P1 site had a significant impact on the inhibitory activity of chymotrypsin. Then, by replacing the P4 and P7' amino acid residues in CH10, CH11, CH35, and CH51 were obtained, and their inhibitory activity decreased by nearly 7 times, indicating that the P4 and P7' amino acid residues can enhance the intermolecular forces with the active site of chymotrypsin (Table 2). By comparing the differences in inhibitory activity between CH33, CH34, and CH10, it can be seen that the more polar P8' glycine is more conducive to enhancing the intermolecular interaction between it and the protease (Table 2). The elongation of the P5 site (CH25, CH26) and the amino acid substitution of the P4' site (CH18) did not significantly change the inhibitory activity (Table 2, Figures 2, 3, 4). SFTI-1 (GRCTKSIPPICFPD) has a unique structure compared to other protease inhibitor molecules in the BBI family. The structure is unique, containing only one disulfide bond and exhibiting a head-to-tail cyclic structure. Based on the specificity of the chymotrypsin P1 site, the Lys at the P1 site was directly mutated to Tyr or Phe, and polypeptides CH54 and CH55 were designed and synthesized (Table 1). Both exhibited excellent inhibitory activity against chymotrypsin, with IC50 values of [missing information]. 50 The concentrations were 0.03 μM and 0.02 μM, respectively (Figure 5). To further simplify the structure, CH56, CH57, and CH58 were synthesized (Table 1). The inhibition of these three structures shows that the Pro at the P8' position generates steric hindrance, reducing its inhibitory effect and leading to reduced IC50. 50 (0.62μM) relative to CH55 (IC 50 =0.02 μM) decreased by more than 30-fold (Table 2); at the same time, the inhibitory activities of CH57 and CH58 were compared, indicating that Gly at the P5 position is beneficial to enhancing the interaction between the inhibitory peptide and the active site of chymotrypsin, and the amino acid residues at the P5 site have a significant impact on its inhibitory activity; the results also show that CH58 is the core backbone for interaction with the active site of chymotrypsin (Table 2). Meanwhile, the peptide CH59-CH62 (Table 1), which is substituted with amino acids at the P4 and P7' sites, was synthesized. Its inhibitory activity was slightly weaker than that of CH57, and its IC50 of chymotrypsin inhibition was 0.02 μM. 50 The concentrations were 0.18 μM, 0.09 μM, 0.12 μM, and 0.15 μM, respectively (Table 2, Figure 6); a series of disulfide-bonded ring-expanded polypeptides CH65-CH71 were also synthesized based on CH57 (Table 1), among which CH65 and CH68-CH71 showed good inhibitory activity against chymotrypsin, with IC50 values of 0.18 μM, 0.09 μM, 0.12 μM, and 0.15 μM, respectively (Table 2, Figure 6); a series of disulfide-bonded ring-expanded polypeptides CH65-CH71 were also synthesized based on CH57 (Table 1), among which CH65 and CH68-CH71 both showed good inhibitory activity against chymotrypsin, with IC50 values of 0.18 μM, 0.09 μM, 0.12 μM, and 0.15 μM, respectively. 50 The concentrations were 0.48 μM, 0.45 μM, 0.30 μM, 0.25 μM, and 0.41 μM, respectively (Table 2, Figure 7). Table 1. Molecular structure and activity of chymotrypsin inhibitory peptides a: The antichymotrypsin backbone in the table has a disulfide bond between two cysteine residues; Xaa = L-α-Aminobutyric acid, Abu. Table 2. Determination of the activity of chymotrypsin inhibitory peptides *: CH10 has almost no inhibitory activity at a concentration of 0.0001 μM, but the values of two replicates were discarded due to large loading errors. Table 2. Determination of the activity of chymotrypsin inhibitory peptides *: CH10 has almost no inhibitory activity at a concentration of 0.0001 μM, but the values of two replicates were discarded due to large loading errors. Table 2. Assay of the activity of chymotrypsin inhibitory peptides (continued) Table 2. Assay of the activity of chymotrypsin inhibitory peptides (continued) Table 2. Assay of the activity of chymotrypsin inhibitory peptides (continued) Table 2. Assay of the activity of chymotrypsin inhibitory peptides (continued) Example 3 Construction of the methanol yeast expression vector pDeut-Aox1-ScKex2 When using *Saccharomyces cerevisiae* as a host for the secretory expression of heterologous proteins, the most widely used vector is the Invitrogen pPIC9K expression plasmid. However, this vector suffers from problems such as unstable expression of resistance selection markers, only one multiple cloning site (MCS), and low homologous integration efficiency. To improve the integrated expression of heterologous target genes, the plasmid expression vector was modified. The construction process is as follows: (1) A promoter and terminator containing Saccharomyces cerevisiae cytochrome C isoform 1 (CYC1) were artificially synthesized and fused with a fusion expression cassette (SEQ ID NO: 90) encoding the Escherichia coli Kan gene. The fusion gene fragment was then amplified using primers kan-1 / kan-2 (SEQ ID NO: 91 and 92), and directionally subcloned into the original pPIC9K plasmid expression vector using restriction endonucleases BsrGI and NdeI. After ligation (… The plasmid pScCyc1-Kan was obtained by transforming the plasmid using the One Step Cloning Kit (II), screening for positive clones, and sequencing verification. (2) A fusion gene fragment containing the signal peptide and secretory precursor region of *Saccharomyces cerevisiae* αMF (mating factor alpha 1), the terminator of *Methanolacosomalemia* FLD1, and the promoter of DAS2 was artificially synthesized (SEQ ID NO: 93). The entire fusion gene fragment was then amplified using primers A4-B1- / A4-B-2 (SEQ ID NO: 94 and 95), and inserted into the plasmid pScCYC-Kan using the restriction endonuclease BamHI. After ligation... The plasmid pA4-DAS2-Kan was obtained by transforming the plasmid using the One Step Cloning Kit, screening for positive clones, and sequencing verification. (3) Using *Methanolmyces oryzae* genomic DNA as a template, the homologous DNA fragment at the 3' end of the AOX1 gene (SEQ ID NO: 98) was amplified using primers AOX1-3F1 / AOX1-3F2 (SEQ ID NO: 96 and 97). Then, the homologous DNA fragment at the 3' end of the AOX1 gene was inserted using the restriction endonuclease Sap I site, followed by ligation. The plasmid expression vector pDeut-Aox1vector is obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). (4) To promote the secretory expression of insulin or its analogue precursor proteins, it is necessary to enhance the expression of the protease Kex2. Using primers ScKEX2-E1 / ScKEX2-N2 (SEQ ID NO: 99 and 100), the optimized coding frame of the Saccharomyces cerevisiae protease Kex2 (ScKex2, SEQ ID NO: 101) was directly amplified. Subcloning into the expression cassette controlled by the DAS2 promoter using restriction endonucleases EcoRI and NotI achieved high intracellular expression of ScKex2. After ligation (… The plasmid expression vector pDeut-Aox1-ScKex2 (Figure 8) is obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). Example 4. Construction of the gene-edited expression vector pGAD-Cas9-gAOX1 targeting yeast ethanol oxidase 1 (AOX1) Methanol homologous integration is inefficient. To improve its efficiency in directing the entire gene to the AOX1 site in yeast, this invention utilizes gene editing technology with a gRNA-mediated dual plasmid transformation system for targeted integration and expression of the target gene. The gRNA expression vector targeting the AOX1 gene was constructed using plasmid pGADT7 as a backbone. The construction process is as follows: (1) First, a gRNA expression cassette (gAOX1) containing the AOX1 promoter region and the yeast replicon element PARS2 (SEQ ID NO: 102) were artificially synthesized. Then, the fusion gene fragment was directly amplified using primers gRNA-Nhe1 / PARS2-Not1 (SEQ ID NO: 103 and 104). Subcloning was performed using restriction endonucleases Nhe I and Not I to the plasmid pGADT7, followed by ligation. II One Step Cloning Kit), transformation, positive clone screening and sequencing verification The plasmid vector pGADT7-gAOX1 was obtained. (2) Using plasmid pX260(AddGene) containing the Cas9 coding frame as a template, the Cas9 coding frame was directly amplified using primers X260-Nde1 / X260-Xho1 (SEQ ID NO: 105 and 106). The plasmid was then subcloned into plasmid pGADT7-gAOX1 using restriction endonucleases Nde I and Xho I, and ligated. The plasmid vector pCas9-gAOX1 is obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). (3) Using *Saccharomyces cerevisiae* genomic DNA as a template, the promoter (GAD) DNA fragment of the *Saccharomyces cerevisiae* glyceraldehyde-3-phosphate dehydrogenase gene (SEQ ID NO: 109) was amplified using primers GAP_X260-1 / GAP_X260-2 (SEQ ID NO: 107 and 108). Then, it was subcloned into plasmid pCas9-gAOX1 using restriction endonucleases Cla I and Nde I, and ligated (…). The plasmid vector pGAD-Cas9-gAOX1 (Figure 9) was obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). Example 5. Construction of a precursor protein expression vector containing a hybrid peptide of insulin or its analogues Methanol yeast cells are eukaryotic mononuclear cells with strong secretory expression capabilities and are easily cultured for fermentation. This invention uses the signal peptide and precursor region of *Saccharomyces cerevisiae* αMF to guide the secretory expression of hybrid peptide precursor proteins. First, the hybrid peptide precursor protein translated in the endoplasmic reticulum (ER) is cleaved by a signal enzyme to remove the αMF signal peptide, then transported to the trans Golgi apparatus. Next, yeast ScKex2, which highly expresses and localizes to the trans Golgi apparatus, cleaves the precursor region of αMF and the C-peptide or linker between the B-chain and A-chain in the insulin or its analogue hybrid peptide. This is then packaged and secreted extracellularly in the trans Golgi apparatus. After affinity chromatography purification, the fused peptide and its linker are removed by the tobacco mosaic virus protease TEV. Finally, the target protein is purified. Figure 10 briefly outlines the process from hybrid peptide precursor protein to mature hybrid peptide. The detailed construction process of the hybrid peptide precursor protein coding frame is as follows: (1) Precursor protein expression vector for human insulin or its analogues: Precursor protein encoding genes with different B-chains but the same A-chain (SEQ ID NO: 29) were artificially synthesized (Table 3). Then, the DNA coding frame was directly amplified using synthesized primers Ins-BamH1 / Ins-Spe1 (SEQ ID NO: 118 and 119) (Table 4). The gene was subcloned into the expression plasmid pDeut-Aox1-ScKex2 using restriction endonucleases BamHI and SpeI. After ligation… The expression plasmid vectors pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 were obtained through transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). Purification... The confirmed positive clone plasmid was linearized using the restriction endonuclease Pme I and then electrotransformed into GS115 yeast cells along with the gRNA expression plasmid pGAD-Cas9-gAOX1. Table 3. Genes encoding human insulin or its analogue precursor proteins. (2) Precursor protein expression vector for human insulin or its analogues with N-terminus fused to chymotrypsin inhibitory peptide. Using the constructed plasmids pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 containing insulin or its analogue precursor proteins as templates, PCR amplification of DNA fragments encoding the signal peptide and precursor region of αMF was performed using primers AOX1-P1 / CH57-B-N1 or AOX1-P1 / CH10-B-N1 (Table 4), respectively. Similarly, PCR amplification of DNA fragments encoding insulin or its analogue precursor proteins was performed using primers CH57-B-N2 / TFLD1-R1 or CH10-B-N2 / TFLD1-R1 (Table 4). The DNA amplified by these two PCR methods... The fragment was subjected to SOE-PCR completion reaction, and then the product of the PCR completion reaction was used as a template to amplify the coding frame (ORF) of the fusion of the chymotrypsin inhibitory peptide with the N-terminus of the B-chain of insulin or its analogue using primers Ins-BamH1-2 / Ins-Spe1 (Ins-Spe1-1). Finally, it was ligated ( The expression plasmid vectors pIns1-B-CH57N, pIns2-B-CH57N, pIns3-B-CH57N, pIns4-B-CH57N, pIns1-B-CH10N, pIns2-B-CH10N, pIns3-B-CH10N, and pIns4-B-CH10N are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. (3) Precursor protein expression vector for human insulin or its analogues with C-terminus fused to chymotrypsin inhibitory peptide. Using the constructed proprotein expression plasmids pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 containing insulin or its analogues as templates, primers AOX1-P1 / Ins1-B-CH57C1 or AOX1-P1 / Ins1-B-CH10C1, AOX1-P1 / Ins2-B-CH57C1 or AOX1-P1 / Ins2-B-CH10C1, AOX1-P1 / Ins3-B-CH57C1 or AOX1-P1 / Ins3-B-CH10C1, and AOX1-P1 / Ins3-B-CH57C1 or AOX1-P1 / Ins3-B-C H10C1 (Table 4) was used to amplify the signal peptide, precursor region, and B-chain encoding DNA fragments of insulin or its analogues using PCR. Simultaneously, primers Ins1-B-CH57C2 / TFLD1-R1 or Ins1-B-CH10C2 / TFLD1-R1 (Table 4) were used to amplify the four DNA fragments encoding the corresponding linker peptide and A-chain precursor protein of insulin or its analogues. The amplified DNA fragments were then subjected to corresponding SOE-PCR completion reactions. Using the PCR completion reaction product as a template, primers Ins-BamH1 / Ins-Spe1 (or Ins-Spe1-1) were used to amplify the fusion coding frame (ORF) of the C-terminus of the B-chain of insulin or its analogues fused with a chymotrypsin inhibitory peptide. Finally, the ORF was ligated... The expression plasmid vectors pIns1-B-CH57C, pIns2-B-CH57C, pIns3-B-CH57C, pIns4-B-CH57C, pIns1-B-CH10C, pIns2-B-CH10C, pIns3-B-CH10C, and pIns4-B-CH10C are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. Using plasmids pIns1-B-CH57C, pIns2-B-CH57C, pIns3-B-CH57C, pIns4-B-CH57C, pIns1-B-CH10C, pIns2-B-CH10C, pIns3-B-CH10C, and pIns4-B-CH10C as templates, PCR amplification was performed using AOX1-P1 / CH57-G-R1 or AOX1-P1 / CH10-G-R1 (Table 4) to amplify the entire coding frame DNA fragments encoding the C-terminal fusion chymotrypsin inhibitor peptide of the B-chain of αMF and insulin or its analogues. Simultaneously, primers CH-G-F1 / TFLD1-R1 (Table 4) were used to amplify the aforementioned 8 precursor protein coding regions corresponding to the insulin or analogue linker peptides and the A-chain, respectively. The PCR-amplified DNA fragments... A corresponding SOE-PCR completion reaction was performed. Using the PCR completion reaction product as a template, the fusion coding frame (ORF) of the B-chain C-terminus fusion chymotrypsin inhibitor peptide of insulin or its analogues was amplified by PCR using primers Ins-BamH1 / Ins-Spe1. The C-peptide was replaced with a more flexible linker peptide (linker sequence GGSGGSG). Finally, the linker was ligated... The expression plasmid vectors pIns1-B-CH57CT, pIns2-B-CH57CT, pIns3-B-CH57CT, pIns4-B-CH57CT, pIns1-B-CH10CT, pIns2-B-CH10CT, pIns3-B-CH10CT, and pIns4-B-CH10CT are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. (4) Precursor protein expression vector for human insulin or its analogues with N-terminus fused to chymotrypsin inhibitory peptides. Using the constructed proton expression plasmids pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 containing insulin or its analogues as templates, PCR amplification was performed using primers AOX1-P1 / Ins-A-CH57N1 and AOX1-P1 / Ins-A-CH10N1 (Table 4) to amplify DNA fragments encoding the signal peptide, proton region, and B-chain and linker peptide of insulin or its analogues, respectively. The DNA fragments were then amplified using primers Ins-A-... PCR amplification was performed using CH57N2 / TFLD1-R1 or Ins-A-CH10N2 / TFLD1-R1 (Table 4) to amplify the four precursor protein coding regions encoding the corresponding linker peptides and A-chains of insulin or its analogues, respectively. The PCR-amplified DNA fragments were then subjected to corresponding SOE-PCR completion reactions. Using the PCR completion reaction product as a template, PCR amplification was performed using primers Ins-BamH1 / Ins-Spe1 (or Ins-Spe1-1) to amplify the fusion coding frame (ORF) of the A-terminus of the A-chain of insulin or its analogues fused with a chymotrypsin inhibitory peptide. Finally, the ORF was ligated... The expression plasmid vectors pIns1-A-CH57N, pIns2-A-CH57N, pIns3-A-CH57N, pIns4-A-CH57N, pIns1-A-CH10N, pIns2-A-CH10N, pIns3-A-CH10N, and pIns4-A-CH10N are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. (5) Precursor protein expression vector for human insulin or its analogues with C-terminus fused to chymotrypsin inhibitory peptides. Using the constructed pro-insulin or analogue protein expression plasmids pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 as templates, PCR amplification was performed using primers AOX1-P1 / Ins-A-CH57C1 and AOX1-P1 / Ins-A-CH10C1 (Table 4) to amplify DNA fragments encoding the signal peptide, precursor region, and B-chain, linker peptide, and A-chain of insulin or analogues. Similarly, PCR amplification was performed using primers Ins-A-CH57C2 / TFLD1-R1 or Ins-A-CH10C2 / TFLD1-R1 (Table 4) to amplify the precursor protein coding regions of the corresponding linker peptides and A-chains of the above four insulin or analogues. The PCR-amplified DNA fragments were then subjected to corresponding SOE-PCR. The product of the PCR completion reaction was used as a template, and the fusion coding frame (ORF) of the A-chain C-terminus fusion chymotrypsin inhibitor peptide of insulin or its analogues was amplified by PCR using primers Ins-BamH1 / Ins-Spe1. Finally, the ORF was ligated. The expression plasmid vectors pIns1-A-CH57C, pIns2-A-CH57C, pIns3-A-CH57C, pIns4-A-CH57C, pIns1-A-CH10C, pIns2-A-CH10C, pIns3-A-CH10C, and pIns4-A-CH10C are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. Then, using plasmids pIns1-A-CH57C, pIns2-A-CH57C, pIns3-A-CH57C, pIns4-A-CH57C, pIns1-A-CH10C, pIns2-A-CH10C, pIns3-A-CH10C, and pIns4-A-CH10C as templates, PCR amplification of DNA fragments encoding the signal peptide, precursor region, and B-chain of insulin or its analogues was performed using primers AOX1-P1 / A-CH-LR1 (Table 4). Simultaneously, primers A-CH-L... R2 / TFLD1-R1 (Table 4) were used to PCR amplify the above 8 DNA fragments encoding the corresponding linker peptides and A-chain precursor proteins of insulin or its analogues. The PCR-amplified DNA fragments were then subjected to corresponding SOE-PCR completion reactions. Using the PCR completion reaction product as a template, primers Ins-BamH1 / Ins-Spe1 were used to PCR amplify the coding frame (ORF) of the C-terminus fusion chymotrypsin inhibitor peptide of the A-chain of insulin or its analogues. The linker peptide between the B-chain and A-chain of insulin or its analogues was replaced with SEQ ID NO:70 (RREAEDGSGGSGENLYFQ). Finally, ligation was performed (…). The expression plasmid vectors pIns1-A-CH57CT, pIns2-A-CH57CT, pIns3-A-CH57CT, pIns4-A-CH57CT, pIns1-A-CH10CT, pIns2-A-CH10CT, pIns3-A-CH10CT, and pIns4-A-CH10CT are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. (6) Precursor protein expression vector for human insulin or its analogues with intermediate A-chain fused to chymotrypsin inhibitory peptide Using the constructed proprotein expression plasmids pAOX1-ScKex2-Ins-1, pAOX1-ScKex2-Ins-2, pAOX1-ScKex2-Ins-3, and pAOX1-ScKex2-Ins-4 containing insulin or its analogues as templates, PCR amplification was performed using primers AOX1-P1 / Ins-A-CH57M1 and AOX1-P1 / Ins-A-CH10M1 (Table 4), respectively, to encode the signal peptide, progenitor region, and B-chain, linker peptide, and partial expression region of insulin or its analogues encoding αMF. DNA fragments of the A-chain were used, and PCR amplification of the corresponding linker peptides and partial A-chain precursor protein coding regions of the above four insulin or analogues was performed using primers Ins-A-CH57M2 / TFLD1-R1 or Ins-A-CH10M2 / TFLD1-R1 (Table 4). The PCR-amplified DNA fragments were then subjected to corresponding SOE-PCR completion reactions. Using the PCR completion reaction product as a template, PCR amplification of insulin or its analogues was performed using primers Ins-BamH1 / Ins-Spe1 (or Ins-Spe1-1). The analogue A-chain inserts a fusion coding frame (ORF) for a chymotrypsin inhibitor peptide into the middle, and finally links ( The expression plasmid vectors pIns1-A-CH57M, pIns2-A-CH57M, pIns3-A-CH57M, pIns4-A-CH57M, pIns1-A-CH10M, pIns2-A-CH10M, pIns3-A-CH10M, and pIns4-A-CH10M are obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit. Table 4 Primers used to construct hybrid peptide precursor protein expression vectors for human insulin or its analogues Example 6. Electroporation method for DNA transformation, screening of positive transformants, and induction of target protein expression in *Saccharomyces cerevisiae*: (1) Pick a single colony from a freshly activated Pichia pastoris GS115 plate and incubate it in 5-10 mL of YPD liquid medium at 30°C and 220 rpm for 8-10 hours. Transfer it to fresh YPD medium at a ratio of 1.2-1.5% (V / V) and incubate it overnight under the same conditions. (2) OD of the bacterial culture 600nm When the value is 1.3 to 1.5, collect 4 to 6 mL of bacterial culture into a 1.5 mL centrifuge tube and centrifuge at 8000 rpm for 5 minutes. (3) Wash the bacterial cells twice with 1 mL of pre-cooled sterile water and twice with 1 mL of 1 M sterile sorbitol solution. After each wash, centrifuge at 8000 rpm for 5 minutes. (4) After centrifugation, the bacterial cells are resuspended in 80 μL of 1M pre-cooled sterile sorbitol solution every 4-6 mL to obtain a tube of competent cells. (5) Mix one tube of GS115 competent cells with 2–3 μg (volume not exceeding 10 μL) of the target DNA fragment, add it to a pre-chilled sterile electroporation cuvette, and incubate on ice for 5 minutes. Wipe the water droplets off the outside of the electroporator, select the Pichia pastoris option ("Pic") on the electroporator, record the corresponding parameters after electroporation, and immediately add 1 mL of 1M pre-chilled sterile sorbitol YPD solution, incubate on ice for 1 hour. Incubate at 30°C for 4–6 hours to rejuvenate. Gently mix with a pipette, and spread 200 μL onto a YPD-resistant plate. Incubate at 30°C for 2–4 days. Yeast genome extraction: Follow the instructions in the yeast genome extraction kit: (1) Take 1-5 mL of yeast culture (not exceeding 5 × 10⁻⁵ mL) 7 Centrifuge yeast cells at 12,000 rpm for 1 minute and remove as much supernatant as possible. (2) Disruption of yeast cell walls: Add 600 μL of snailase to the cells, mix thoroughly, and treat on a shaker at 220 rpm and 30°C for 2 hours. Centrifuge at 4000 rpm for 10 minutes, discard the supernatant, and collect the precipitate. (3) Add 200 μL of buffer GA to resuspend and mix thoroughly. (4) Add 20 μL of Proteinase K solution and mix well. (5) Add 220 μL of buffer GB, mix thoroughly by inverting, place at 70°C for 10 minutes, the solution should become clear, and briefly centrifuge to remove water droplets from the tube wall. (6) Add 220 μL of anhydrous ethanol, mix thoroughly by inverting, and briefly centrifuge to remove water droplets from the tube wall. (7) Add the solution and flocculent precipitate obtained in the previous step to an adsorption column CB3 (place the adsorption column in the collection tube), centrifuge at 12000 rpm for 30 s, discard the waste liquid, and put it back into CB3. (8) Add 500 μL of buffer GD to the adsorption column CB3, centrifuge at 12000 rpm for 30 s, discard the waste liquid, and put it back into CB3. (9) Add 600 μL of wash buffer PW to the adsorption column CB3, centrifuge at 12000 rpm for 30 s, discard the waste liquid, and return it to CB3. Repeat once. (10) Place the adsorption column CB3 into the collection tube and centrifuge at 12000 rpm for 2 minutes, then let it stand at room temperature for 10 minutes to remove the residual ethanol in the adsorption column. (11) Place the adsorption column CB3 in a clean centrifuge tube, add 50 μL ddH2O to the center of the adsorption membrane, incubate at 37℃ for 15 min, and centrifuge at 12000 rpm for 2 min to collect the plasmid solution into the centrifuge tube. PCR identification of positive clones: Positive clones were screened using YPD solid medium containing 100 μg·mL⁻¹ G418 resistance. Genomic DNA was extracted from six randomly selected positive clones of the recombinant strain. A first round of PCR amplification was performed using primers AOX1_P1 / TFLD1-R1, followed by a second round of PCR verification using primers AOX1_P2 / Ins-Spe1. The amplified bands of the target gene in positive clones were approximately 1 kb. The DNA fragments were purified and recovered, and then sequenced for verification. Rapid screening of target protein expression: Selected single clones identified by PCR were inoculated into 4 mL of BMGY medium and cultured at 28°C and 240 RPM for approximately 16-20 hours. OD 600 =8-10. Press OD 600 =1 Transfer to 4 mL BMMY, and continue culturing at 28℃ and 240 RPM for 72-96 h, adding 1-1.5% anhydrous methanol daily. Perform dot-blotting hybridization using a Bio-Dot Apparatus (Bio-rad) microfiltration system, and select clones with strong hybridization signals for shake-flask fermentation. Expression and purification of the target protein: Positive clones with high expression levels of the target protein were selected by dot blot screening and induced to ferment in 1L shake flasks containing 250mL of BMMY medium. After fermentation for 72-96 hours, the supernatant was collected by centrifugation. The extracellular secreted protein was then purified by nickel affinity chromatography. The target protein was obtained by elution using an imidazole gradient. Example 7. Expression, purification, and enzymatic digestion of proteases TEV and PAM Construction of TEV enzyme expression vector: This invention selects the cold shock induced expression system pCold-MBP (Takara) The company used Shuffle T7 host bacteria for heterologous expression to increase protein solubility and promote correct protein folding. To facilitate the purification of the target protein using His-Tag, the DNA fragment on plasmid pCold-MBP was first amplified by PCR using primers Cold-Nhe1 / Cold-Nde1 (SEQ ID NO:154 and 155) (Table 5). Then, the corresponding vector structure fragment on the vector was replaced by restriction endonucleases Nhe I and Nde I to remove the His-Tag tag at the N-terminus of the MBP tag that promotes soluble expression, thus obtaining plasmid pCold-MBP-T. Then, the synthetic tobacco mosaic virus protease TEV coding frame (SEQ ID NO:158) was directly amplified using primers TEV-BamH1 / TEV-Sal1 (SEQ ID NO:156 and 157) (Table 5). The restriction endonucleases BamH I and Sal I were used to directionally insert it into plasmid pCold-MBP-T, and then ligated ( The expression plasmid vector pCold-TEV is obtained through transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II), which enables soluble expression of TEV and self-cleavage of the fusion tag MBP. An expression vector for peptidylglycine alpha-amidating monooxygenase (PAM) was constructed: PAM contains two catalytic domains: peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidylamidoglycolate lyase (PAL). Using the plasmid pReceiver-M02 (GeneCopoeia) containing the PAM gene (GenBank: NM_000919) as a template, DNA fragments containing the PHM domain encoding amino acid residues 39-350 and the PAL domain encoding amino acid residues 494-835 were amplified by PCR using primers pReceiver-M03F / PAM-1 (SEQ ID NO: 159 and 161) and PAM-2 / pReceiver-M03R (SEQ ID NO: 160 and 162) (Table 5). These two DNA fragments were then subjected to PCR completion reaction. Using the PCR completion reaction product as a template, the truncated PAM mutant was amplified by PCR using primers PAM-BamH1 / PAM-Sal1 (SEQ ID NO: 163 and 164) (Table 5), in which a linker peptide (GSGGSG) was introduced between the two domains. The restriction endonuclease was used to directionally insert the restriction endonuclease into the plasmid pCold-MBP-T, followed by ligation. The expression plasmid vector pCold-PAM is obtained by transformation, positive clone screening, and sequencing verification using the One Step Cloning Kit (II). The N-terminal fusion tag MBP can be removed by TEV enzyme cleavage. The two proteases mentioned above were purified by nickel ion affinity chromatography to obtain the proteases. Then, an enzymatic digestion reaction system containing insulin or its analogue hybrid peptide was established: 50 mM Hepes (pH 7.0), 1 μM CuSO4, 50 μg / ml catalase, 1 mM ascorbate, a precursor protein substrate, protease TVE, and PAM were added. The precursor protein was directly digested at 30°C. After the reaction, [the following was added] The enzymatic digestion reaction was inactivated using 1 / 10 volume of 0.1M EDTA and 50% TFA. Finally, the reaction buffer (1.0 mM NiCl2, 0.1 M CHES, 0.1 M acetone oxime, 0.1 M NaCl, pH 8.2) was replaced with nickel ion-induced shear fusion tag (G↓SRHW) reaction buffer by ultrafiltration concentration and reacted at 22°C for 16 h. The resulting product was then directly purified by RP-HPLC to obtain the hybrid peptide containing insulin or its analogues provided by this invention. Table 5 Primers used to construct the TEV and PAM expression vectors for proteases Example 8. Stability analysis of hybrid peptides of insulin or its analogues against chymotrypsin digestion. Control experiment: Take three sterile EP tubes, add 1.5 μL of 1 mM insulin or its analogue hybrid peptide, 23.5 μL of 50 mM Tris and 20 mM CaCl2 (pH 7.8) buffer and 3.75 μL of 10% TFA to each EP tube, and centrifuge at 8000 rpm for 30 s to mix. The enzymatic digestion of human insulin, insulin analogs, and their hybrid peptides with chymotrypsin is as follows: Take three sterile EP tubes, and add 9 μL of 1 mM human insulin, insulin analogs, and their hybrid peptides, along with 138 μL of 20 mM CaCl2 and 50 mM Tris-HCl buffer (pH 7.8) to each EP tube. Simultaneously, prepare a specific volume of 0.05 μg / μL chymotrypsin enzyme solution in another sterile EP tube. Then, simultaneously incubate the four EP tubes containing the peptides and enzymes at 37°C for 5 min. Add 3 μL of chymotrypsin to each EP tube containing the peptides. Mix the chymotrypsin enzyme solution thoroughly. Start timing and take out 25 μL of the reaction solution at 0.5, 1.0, 2.0, 3.0 and 4.0 h respectively. Add 3.75 μL of 10% TFA to terminate the reaction and centrifuge at 8000 rpm for 30 s to mix. In the above experimental samples, the final concentration of human insulin, insulin analogs and their hybrid peptides was 60 μM in a 25 μL reaction system, and the final concentration of chymotrypsin was 1.0 ng / μL. Each time point was repeated three times. The peak area of the peptide at each time point was detected using RP-HPLC, and the percentage of remaining peptide (%) was calculated as the ratio of the remaining peak area of the sample at detection time T (h) to the peak area of the prototype peptide at 0 h. Results: After 4 hours of chymotrypsin digestion, only about 10.3% of human insulin remained, indicating low stability against chymotrypsin digestion. However, the insulin analog hybrid peptides containing the chymotrypsin inhibitory backbone CH57 or CH10 exhibited very good stability against trypsin digestion, with more than 80% remaining after 4 hours of digestion. Table 6: Stability analysis of human insulin and its hybrid peptides (Ins3-A-CH10M and Ins3-A-CH57M) to chymotrypsin Example 9. In vivo activity of insulin or its analogues and insulin hybrid peptides via subcutaneous injection and duodenal administration In vivo hypoglycemic activity of insulin analogs and insulin hybrid peptides administered subcutaneously: Normal ICR mice were subcutaneously injected with humulin (0.4 U / kg) and insulin analogs or an equivalent volume of physiological saline (0.1 mL / 10 g BW, n = 6-9). Blood samples were collected from the tail tip at 40 min and 90 min after administration, and blood glucose levels were measured using the glucose oxidase method. Blood glucose values at each time point were calculated. Calculated values are expressed as mean ± standard error, and p < 0.05 was considered statistically significant. Results: Insulin analogs such as insulin lispro (LisPro) showed excellent hypoglycemic activity compared to the positive control; similarly, insulin hybrid peptides containing chymotrypsin inhibitory peptides (Ins3-B-CH57N, Ins3-B-CH57C, Ins3-A-CH10M, Ins3-A-CH57M) also showed excellent hypoglycemic activity (Table). 7); This indicates that no structural chymotrypsin inhibitory peptide was observed to affect its interaction with the insulin receptor, whether at the N-terminus, C-terminus, or middle of the B-chain. However, the chymotrypsin inhibitory peptides fused to the N-terminus and C-terminus of the A-chain prepared by biological expression showed weak activity (Ins3-A-CH57N and Ins3-A-CH57C), which may be due to the absence of a correct disulfide bond structure, and could be a false negative result. Table 7: Hypoglycemic activity of human insulin and its analogues administered subcutaneously * p<0.05; ** p<0.01; *** p < 0.001. Table 7: Hypoglycemic Activity of Human Insulin and its Analogs via Subcutaneous Administration (Continued) * p<0.05; ** p<0.01; *** p < 0.001. In vivo hypoglycemic activity of insulin analogs and insulin hybrid peptides administered via the duodenum: In normal ICR mice, after anesthesia with inhaled ether, the duodenum was surgically removed, and an insulin analog or an appropriate volume of physiological saline (0.1 mL / 10 g BW, n = 6-10) was injected. The wound was then sutured, and blood samples were collected from the tail tip at 40 min and 90 min after administration. Blood glucose levels were measured using the glucose oxidase method, and blood glucose values at each time point were calculated. Calculated values are expressed as mean ± standard error, and p < 0.05 was considered statistically significant. Results: Compared with the normal control group, only insulin hybrid peptides Ins3-B-CH57C, Ins3-A-CH10M, and Ins3-A-CH57M, administered duodenally, significantly reduced blood glucose levels in mice over 40 minutes, decreasing by 12.1%, 11.9%, and 15.3%, respectively (Table 8). This indicates that the chymotrypsin inhibitory peptide, located at the C-terminus of the B-chain and the middle of the A-chain, provides excellent protection against insulin, enhancing its in vivo stability and promoting the absorption of the insulin hybrid peptide into the bloodstream via the small intestinal epithelium. Table 8: Hypoglycemic activity of human insulin and its analogues administered duodenally * p<0.05; ** p<0.01; *** p < 0.001. Table 8: Hypoglycemic Activity of Human Insulin and its Analogs via Duodenal Administration (Continued) * p<0.05; ** p<0.01; *** p < 0.001.
Claims
1. A hybrid peptide formed from insulin or an analogue thereof and a chymotrypsin inhibitory peptide, wherein the two are linked by a linker peptide; wherein the insulin or analogue thereof contains a B-chain and an A-chain and is linked by two pairs of disulfide bonds; wherein the chymotrypsin inhibitory peptide is linked to the B-chain or A-chain of the insulin or analogue by the linker peptide. 。 2. The hybrid peptide according to claim 1, wherein its characteristics are... The characteristic is that the chymotrypsin inhibitory peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27 and SEQ ID NO: 28。 3. The hybrid peptide according to claim 1, The insulin or its analogues are characterized in that they comprise an A-chain and a B-chain; wherein the A-chain may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33; and the B-chain may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:30, SEQ ID NO:31, SEQ ID NO:32, SEQ ID NO:33; O:40。 4. The hybridization according to claim 1 The peptide is characterized in that the linking peptide between the insulin or its analogue and the chymotrypsin inhibitory peptide is a peptide containing Gly, Ser, and Pro amino acid residues and having a length of one or more amino acid residues. Peptide segments or deletions.
5. The method according to claims 1-3 The hybrid peptide is characterized by having a structural domain from the N-terminus to the C-terminus as follows: (N-terminus)-chymotrypsin inhibitor-insulin B-chain---insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the B-chain of insulin or its analogue via a linker peptide; the "(N-terminus)-chymotrypsin inhibitor-insulin B-chain" is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin B-chain, which may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; ID NO:
33.
6. According to claim 5 The hybrid peptide described herein is characterized in that the hybrid peptide precursor protein has the following domain from the N-terminus to the C-terminus: (N-terminus)-chymotrypsin inhibitor-insulin B-chain-C-peptide-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the B-chain of insulin or its analogue via a linker peptide; the "(N-terminus)-chymotrypsin inhibitor-insulin B-chain" is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin B-chain, which may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49 and SEQ ID NO:50; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70 ... NO:71; Among them, the precursor protein is subjected to three steps of treatment: cleavage by protease Kex2, cleavage by tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage, and / or carboxypeptidase B and peptidyl glycine α-amidation monoclonal antibody. Treatment or non-treatment of oxygenase.
7. According to the claims 6. The hybrid peptide described above is characterized in that the hybrid peptide precursor protein is selected from polypeptides having the following amino acid sequences: SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169, SEQ ID NO:170, SEQ ID NO:171, SEQ ID NO:172, SEQ ID NO:173 and S. EQ ID NO:174; 8. According to the claims The hybrid peptides described in 1-3 are characterized by having a structural domain from the N-terminus to the C-terminus as follows: (N-terminus)-insulin B-chain-chymotrypsin inhibitor---insulin A-chain-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the B-chain of insulin or its analogue via a linker peptide; the "(N-terminus)-insulin B-chain-chymotrypsin inhibitor" is a polypeptide formed by the fusion of the insulin B-chain and the chymotrypsin inhibitor, which may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57 and SEQ ID NO:58; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:3 1. SEQ ID NO:
33.
9. According to The hybrid peptide of claim 8 is characterized in that the hybrid peptide precursor protein has the following domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-chymotrypsin inhibitor-C-peptide-insulin A-chain-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the B-chain of insulin or its analogue via a linker peptide; the "(N-terminus)-insulin B-chain-chymotrypsin inhibitor" is a polypeptide formed by the fusion of the insulin B-chain and the chymotrypsin inhibitor, which may be selected from polypeptides having the following amino acid sequences: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57 and SEQ ID NO:58; the A-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:72 and SEQ ID NO:
58. NO:73; Among them, the precursor protein is subjected to three steps of treatment: enzyme digestion by protease Kex2, tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage, and / or carboxypeptidase B and peptidyl glycine. Treatment or no treatment of α-amidyloxygenase. 10 According to claim 9, the hybrid peptide is characterized in that the hybrid peptide precursor protein is selected from polypeptides having the following amino acid sequences: SEQ ID NO:185, SEQ ID NO:186, SEQ ID NO:187, SEQ ID NO:188, SEQ ID NO:189, SEQ ID NO:190, SEQ ID NO:191, SEQ ID NO:192, SEQ ID NO:193, SEQ ID NO:194, SEQ ID NO:195, SEQ ID NO:19 ...97, SEQ ID NO:188, SEQ ID NO:189, O:195 and SEQ ID NO:
196. 1 1. The hybrid peptide according to claims 1-3, characterized in that its structural domain from the N-terminus to the C-terminus is: (N-terminus)-insulin B-chain---chymotrypsin inhibitory peptide-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitory peptide is directly fused to the N-terminus of the A-chain of insulin or its analogue via a linker peptide, and the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "chymotrypsin inhibitory peptide-insulin A-chain-(C-terminus)" is a polypeptide formed by the fusion of the chymotrypsin inhibitory peptide and the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:40, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:40, SEQ ID NO:39, SEQ ID NO:3 ... ID NO:61、SEQ ID NO:6 2。 12. The hybrid peptide according to claim 11, characterized in that the hybrid peptide precursor protein has the following domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-chymotrypsin inhibitor-insulin A-chain-(C-terminus), wherein the C-terminus of the chymotrypsin inhibitor is directly fused to the N-terminus of the A-chain of insulin or its analogue via a linker peptide, and the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "chymotrypsin inhibitor-insulin A-chain-(C-terminus)" is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:62; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "chymotrypsin inhibitor-insulin A-chain-(C-terminus)" is a polypeptide formed by the fusion of the chymotrypsin inhibitor and the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:69, SEQ ID NO:60, NO:71; Among them, the precursor protein undergoes three steps of treatment: enzyme digestion by Kex2, tobacco mosaic virus enzyme TEV, and nickel ion-induced chemical cleavage, and / or carboxylation. Treatment with peptidase B and peptidyl glycine α-amidyloxygenase Or do not process it.
13. The hybrid peptide according to claim 12, wherein the hybrid peptide precursor protein is selected from polypeptides having the following amino acid sequences: SEQ ID NO:209, SEQ ID NO:210, SEQ ID NO:211, SEQ ID NO:212, SEQ ID NO:213, SEQ ID NO:214, SEQ ID NO:215, SEQ ID NO:216 SEQ ID NO:217 and SEQ ID NO:
218.
14. The hybrid peptide according to claims 1-3, characterized in that its structural domain from the N-terminus to the C-terminus is: (N-terminus)-insulin B-chain-insulin A-chain-chymotrypsin inhibitor-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the A-chain of insulin or its analogue via a linker peptide; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-(C-terminus)" is a polypeptide formed by the fusion of the insulin A-chain and the chymotrypsin inhibitor, selected from polypeptides having the following amino acid sequences. Polypeptide sequence: SEQ ID NO:63, SE Q ID NO:
64.
15. The hybrid peptide according to claim 14, characterized in that the hybrid peptide precursor protein has the following domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-insulin A-chain-chymotrypsin inhibitor-(C-terminus), wherein the N-terminus of the chymotrypsin inhibitor is directly fused to the C-terminus of the A-chain of insulin or its analogue via a linker peptide; the B-chain of insulin or its analogue is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-(C-terminus)" is a polypeptide formed by the fusion of the insulin A-chain and the chymotrypsin inhibitor, selected from polypeptides having the following amino acid sequences: SEQ ID NO:63, SEQ ID NO:64; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:71; wherein the precursor protein is cleaved by protease Kex2, tobacco mosaic virus protease TEV, and nickel ion-induced chemical cleavage. Three-step processing, and / or carboxypeptidase B and peptidyl glycine α-acyl Treatment or no treatment of amination monooxygenase.
16. The hybrid peptide according to claim 15, characterized in that the hybrid peptide precursor protein is selected from polypeptides having the following amino acid sequences: SEQ ID NO:229, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:236, SEQ ID NO:237, SEQ ID NO:238, SEQ ID NO:239, SEQ ID NO:239, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO:234, SEQ ID NO:235, SEQ ID NO:239, SEQ ID NO:239, SEQ ID NO:230, SEQ ID NO:231, SEQ ID NO:232, SEQ ID NO:233, SEQ ID NO: ID NO:236、SEQ ID NO:23 7 and SEQ ID NO:
238.
17. The hybrid peptide according to claims 1-3, characterized in that its structural domain from the N-terminus to the C-terminus is: (N-terminus)-insulin B-chain--insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus), wherein the chymotrypsin inhibitor directly forms a fusion peptide with the A-chain of insulin or its analogue; the insulin or analogue B-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus)" is a polypeptide formed by fusing the chymotrypsin inhibitor in the middle of the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:6 5、SEQ ID NO:66、SEQ ID NO:67, SEQ ID NO:
68.
18. The hybrid peptide according to claim 17, characterized in that the hybrid peptide precursor protein has the following domain from the N-terminus to the C-terminus: (N-terminus)-insulin B-chain-C-peptide-insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus), wherein the chymotrypsin inhibitor directly forms a fusion peptide with the A-chain of insulin or its analogue; the insulin or analogue B-chain is selected from polypeptides having the following amino acid sequences: SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:39, SEQ ID NO:40; the "insulin A-chain-chymotrypsin inhibitor-A-chain-(C-terminus)" is a polypeptide formed by fusing the chymotrypsin inhibitor in the middle of the insulin A-chain, selected from polypeptides having the following amino acid sequences: SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68; the C-peptide is selected from polypeptides having the following amino acid sequences: SEQ ID NO:70, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68; NO:71; Among them, the precursor protein was cleaved by protease Kex2, tobacco mosaic virus protease TEV and Nickel ion-induced chemical cleavage in three steps, and / or carboxypeptidase B. Treatment or no treatment of peptidyl glycine α-amidyl monooxygenase.
19. The hybrid peptide according to claim 18, characterized in that the hybrid peptide precursor protein is selected from polypeptides having the following amino acid sequences: SEQ ID NO:249, SEQ ID NO:250, SEQ ID NO:251, SEQ ID NO:252, SEQ ID NO:253, SEQ ID NO:254, SEQ ID NO:
255. :255, SEQ ID NO:256, SEQ ID NO:257 and SEQ ID NO:
258.
20. A method for preparing a hybrid peptide containing a chymotrypsin inhibitory peptide and insulin or an analogue thereof as described in claims 1-19, characterized in that the N-terminus of its precursor protein contains a tobacco mosaic virus protease (TEV) cleavage site as shown in SEQ ID NO:69, and the linking peptide between the B-chain and A-chain of the insulin molecule or its analogue is selected from polypeptides with the following sequences: SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72 and SEQ ID NO:73; wherein the precursor protein is subjected to protease Kex2 and tobacco mosaic virus protease... A three-step treatment involving TEV enzyme cleavage and nickel ion-induced chemical cleavage, and / or carboxypeptidase B and peptidyl glycine α-amidation. Treatment or no treatment of monooxygenase.
21. Rights The hybrid peptides in requirements 1-19 are to be used in the preparation of drugs for treating type I or type II diabetes.
22. The application according to claim 21, characterized in that the hybrid peptide can be administered subcutaneously or orally in the treatment of type I and type II diabetes.
